Abstract
A patient with end-stage renal disease received 2 doses of dalbavancin for methicillin-resistant
Staphylococcus aureus arteriovenous fistula infection and presented 5-weeks later with infective endocarditis secondary to vancomycin, daptomycin, and dalbavancin non-susceptible MRSA. Resistance was associated with
walK and
scrA mutations, reduced long-chain lipid content, and reduced membrane fluidity.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου